XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 42.82

Change

-0.03 (-0.07)%

Market Cap

N/A

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.72 (+0.52%)

USD 36.67B
FHLC Fidelity® MSCI Health Care In..

+0.38 (+0.57%)

USD 2.62B
FXH First Trust Health Care AlphaD..

+0.45 (+0.42%)

USD 1.09B
XHE SPDR® S&P Health Care Equipme..

+0.44 (+0.48%)

USD 0.21B
IDNA iShares Genomics Immunology an..

-0.42 (-1.78%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.63 (-1.88%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.79 (+0.84%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.20 (+0.69%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.43 (-0.70%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.38 (-1.54%)

USD 8.55M

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 9.93 % 0.00 %

+0.04 (+0.14%)

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.40% 10% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.40% 10% F 33% F
Trailing 12 Months  
Capital Gain 0.47% 48% F 40% F
Dividend Return 1.59% 100% F 26% F
Total Return 2.06% 57% F 31% F
Trailing 5 Years  
Capital Gain -6.24% 19% F 43% F
Dividend Return 5.63% 68% D+ 15% F
Total Return -0.62% 24% F 28% F
Average Annual (5 Year Horizon)  
Capital Gain -1.55% 14% F 25% F
Dividend Return -0.82% 19% F 17% F
Total Return 0.73% 68% D+ 19% F
Risk Return Profile  
Volatility (Standard Deviation) 16.00% 67% D+ 64% D
Risk Adjusted Return -5.13% 14% F 18% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.